A randomized, double-blind, controlled, small-sample pre-clinical trial of Yiqi Huoxue Powder in the treatment of sepsis
- Conditions
- Sepsis
- Registration Number
- ITMCTR2000003883
- Lead Sponsor
- GuangDong Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients who met the diagnostic criteria of sepsis 3.0 in 2016;
2. Patients who met the diagnostic criteria of pneumonia, and the source of sepsis was pneumonia;
3. Patients aged 18-80 years old;
4. Patients with informed consent.
1. Patients who may die within 24 hours;
2. Patients with serious condition and need cardiopulmonary resuscitation;
3. Patients with advanced malignant tumor with cachexia;
4. Patients with acute coronary artery disease, such as acute myocardial infarction;
5. The patients who are allergic to the prescription of Yiqi Huoxue powder or allergic constitution;
6. Pregnant women;
7. Patients who have participated in other clinical trials in recent 3 months.
8. There are other situations that the clinical researcher thinks is not suitable to participate in the study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 28-day case fatality rate;
- Secondary Outcome Measures
Name Time Method PD-L1;CD14+/HLA-DR;T lymphocyte subsets;PD-1;APACHE? score;Whether PICS occur;Number of days without ventilator support;7 day case fatality rate;Length of stay in ICU;procalcitonin;SOFA score;hs-CRP;Hospitalization days;White blood cell count;